GlassScriptPhysician profile
Michael David Martinez
NPI 1285951210
$4,484.50
in general payments reported to CMS, 2019-2025
29 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $432 · 2021: $500 · 2022: $864 · 2023: $216 · 2024: $273 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $962.83 | 2019-2025 | Eterna, Proclaim |
| Nevro Corp. | $552.93 | 2019-2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $505.34 | 2019-2025 | Austedo Xr, Austedo Xr |
| Stimwave Technologies Incorporated | $411.47 | 2019-2021 | |
| Vgi Medical, LLC | $281.75 | 2022 | |
| Boston Scientific Corporation | $278.86 | 2021-2025 | Intracept, General - Pain Management, Superion Indirect Decompression System |
| Scilex Pharmaceuticals INC. | $246.12 | 2019-2022 | |
| Abbvie INC. | $188.30 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $175.62 | 2019-2022 | |
| Allergan, INC. | $165.19 | 2019-2022 | |
| Medtronic, INC. | $160.44 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Daiichi Sankyo INC. | $68.77 | 2019 | |
| Tersera Therapeutics LLC | $63.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.26 | 2019-2021 | |
| Globus Medical, INC. | $45.47 | 2025 | Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $40.92 | 2020-2021 | |
| Almatica Pharma LLC | $31.43 | 2022-2023 | Gralise |
| Indivior INC. | $30.38 | 2019-2021 | |
| Medtronic USA, INC. | $28.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.68 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $25.63 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.18 | 2019 | |
| Horizon Therapeutics Plc | $18.79 | 2021 | |
| Amgen INC. | $18.61 | 2021 | |
| Kaleo, INC. | $17.76 | 2019 | |
| Painteq LLC | $15.76 | 2024 | Painteq |
| Currax Pharmaceuticals LLC | $13.95 | 2021 | |
| Bioventus LLC | $13.37 | 2019 | |
| Lilly USA, LLC | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.